Liver Resection Versus TACE in Barcelona Clinic Liver Cancer Stage B HCC
Liver resection was found to have significant survival benefits over TACE in patients with Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma (HCC), according to a study published in Hepatology International. However, a significantly increased incidence of treatment-related mortality and infection was associated with liver resection compared to TACE, the authors concluded.
In this comprehensive literature review, researchers identified 11 retrospective or prospective studies evaluating the efficacy of liver resection and TACE for the treatment of BCLC-B HCC by searching EMBASE, PubMed, Google Scholar, and Chinese Biomedical Literature databases for key search terms including “hepatocellular carcinoma”, “liver cancer”, “transarterial chemoembolization”, and “resection.”
The 11 studies included 1688 patients who underwent liver resection and 1678 patients who underwent TACE. Liver resection was found to have a statistically significant survival benefit at 1-year, 3-years, and 5-years overall survival compared to TACE. The incidence of treatment-related mortality and treatment-related infections increased in patients who underwent liver resection, however there was no significant differences in the incidence of treatment-related complications between liver resection and TACE.
“The findings of this meta-analysis suggest that LR has significant survival benefits over TACE in BCLC-B HCC; these data should be interpreted with caution due to selection bias in the analysis. LR was associated with a significantly increased incidence of treatment-related mortality and infection compared to TACE…Additional large-scale, multicenter, randomized controlled trials are required to confirm our findings,” the authors concluded.
Yang B, Zheng B, Yang M, et al. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Hepatol Int. 2018 Aug 2. doi: 10.1007/s12072-018-9888-4. [Epub ahead of print].